
Patent bid sparks cancer-test price fears
Abstracted from The Australian
TOP News
A decision by Genetic Technologies could make breast cancer examinations more expensive, according to Cancer Australia. Genetic holds the Australian and New Zealand patent licences for a test that detects mutations in breast cancer genes, and recently announced plans to use its patent rights to conduct all future testing itself. Women with the defective gene have an 85 per cent change of contracting the disease, against a community-wide average of around nine per cent. Cancer Council Australia CEO, Ian Olver, said allowing genes to be patented could be problematic in the long term and could compromise the Human Genome Project
Distributed by News Bites. © Lexis-Nexis
Related Industry SectorsView the latest stories on Financial Services
View the latest stories on Professional Services
View the latest stories on Health & Pharmaceuticals
Related CompaniesView all stories on GENETIC TECHNOLOGIES
First Anniversary Videos